I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19
In October 2020, the FLCCC Alliance developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called I-Mask+. It’s centered around Ivermectin, a well-known, FDA-approved anti-parasite drug that has been used successfully for more than four decades to treat onchocerciasis “river blindness” and other parasitic diseases. It is one of the safest drugs known. It is on the WHO’s list of essential medicines, has been given 3.7 billion times around the globe, and won the Nobel prize for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world. Our medical Discovery of a rapidly growing published medical evidence base demonstrating its unique and highly potent ability to inhibit SARS-CoV-2 replication and to suppress inflammation, prompted our team to use ivermectin for prevention and treatment in all stages of COVID-19.
Our life-saving MATH+ Hospital Treatment Protocol for COVID-19 (available in several languages), created in March 2020, is intended for hospitalized patients, the recently developed I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 (this page) is designed for use as a prophylaxis and in early outpatient treatment, for those who test positive for COVID-19. The protocols complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All the component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles.
Please download and share our I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19. (It is currently being translated into several languages).
Below are a list of links to our one-page summary of the latest evidence for the protocol, plus videos of FLCCC Alliance doctors discussing the emerging evidence for the use of ivermectin in the prophylaxis and treatment of COVID-19, and a short list of up-to-date studies and clinical trials on this topic.
Publications and videos on the use of ivermectin in our I-MASK+ protocol
- Our comprehensive review of the emerging evidence for Ivermectin use in our I-MASK+ protocol (PDF, continuously updated)
- A one-page summary of the scientific review on ivermectin above (PDF)
- Dr. Paul Marik’s comprehensive meta-analysis of COVID-19 therapeutics (PDF)
- An introductory video explaining the review on Ivermenctin by Dr. Pierre Kory (Vimeo)
- Dr. Paul Marik’s recent lecture on I-MASK+ (YouTube)
- Invited Grand Rounds Lecture on invermectin by Pierre Kory (YouTube)
Please also regard Dr. Paul Marik’s latest
- Guide to the management of COVID-19 – An overview of the FLCCC Alliance’s MATH+ and I-MASK+ protocols (PDF)
Recent studies and clinical trials on ivermectin
Elgazzar A, Basma H, Shaimaa Abo Y, Basma H, Mohy H, Hany M (Research Square; 100956)
A matched case-control study; Behera P, Patro BK, Singh AK, et al. (medRxiv)
Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulamir AS (medRxiv)
Portmann-Baracco A, Bryce-Alberti M, Accinelli RA (NCBI/Arch Bronconeumol/ScienceDirect)
Rajter J-C, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter J-J (ICON study; Chest)
Juan Chamie (ResearchGate)
Dr. Reaz Mahmud, Dhaka Medical College (ClinicalTrials.gov; NCT04523831)
Hector E Carvallo, Eurnekian Public Hospital (ClinicalTrials.gov; NCT04425850)
Waheed Shouman, Zagazig University (ClinicalTrials.gov; NCT04422561)
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (Antiviral Res.; 178:104787)
